Detection of OXA-48 carbapenemase in the pandemic clone Escherichia coli O25b:H4-ST131 in the course of investigation of an outbreak of OXA-48-producing Klebsiella pneumoniae.

Reports of carbapenemase-producing Enterobacteriaceae (CPE) have increased dramatically in the past decade. OXA-48 was first described in Turkey in 2008, and outbreaks of OXA-48-producing Enterobacteriaceae have since been reported worldwide, including Ireland (3, 12, 16). Escherichia coli O25b:H4-ST131 is a very successful uropathogenic clonal group, and its close association with the extended-spectrum -lactamase (ESBL) CTX-M-15 has been implicated in the dissemination of this enzyme (2, 14). We report, for the first time, OXA-48 carbapenemase in a member of the sequence type 131 (ST131) clonal lineage. An 81-year-old male patient (patient 1) (Table 1) was admitted to the medical ward in October 2011 with a diagnosis of lower respiratory tract infection. He had multiple comorbidities and had been treated initially with co-amoxiclav and subsequently with piperacillin-tazobactam. A Klebsiella pneumoniae isolate (isolate number 31799) resistant to amoxicillin, co-amoxiclav, piperacillin-tazobactam, and ertapenem was isolated from a midstream urine and sputum specimen cultured on day eight after admission. On the basis of a preliminary identification as a probable carbapenem-resistant K. pneumoniae isolate, rectal screening of all patients cared for on the same ward was initiated together with measures to control transmission of infection in accordance with draft national guidance (http://www .hpsc.ie/hpsc/A-Z/MicrobiologyAntimicrobialResistance /StrategyforthecontrolofAntimicrobialResistanceinIrelandSARI /CarbapenemResistantEnterobacteriaceaeCRE/). In the course of investigation, carbapenem-resistant K. pneumoniae isolates were identified from six other patients, including patient 2 (Table 1). Patient 2 was an 82-year-old man admitted in late October 2011 with a diagnosis of health care-associated pneumonia. He was treated empirically with piperacillin-tazobactam for 7 days, as he had recently been discharged from a health care facility (9). He had a history of peripheral vascular disease with gangrene of his right foot and multiple comorbidities. He had a recent lengthy hospital stay (August to October 2011) for management of lower limb soft tissue infection and ischemia. On day 10 of his October admission, he developed a progressive soft tissue infection of his right foot. He was treated with broad-spectrum antibiotics for 10 days and required subsequent forefoot amputation. On day 22, in response to the progressive soft tissue infection, piperacillin-tazobactam treatment was commenced and further debridement of his foot was performed. The rectal swab was taken 5 weeks after admission, and in addition to K. pneumoniae (isolate number 110833-3), an Escherichia coli (isolate number 110833-1) isolate was found. Isolate identification was confirmed by Vitek2 (bioMérieux, Hampshire, United Kingdom). Isolates were identified as carbapenemase producers by the modified Hodge method of the Clinical and Laboratory Standards Institute. Results of a commercial synergy test (Rosco Diagnostica, Taastrup, Denmark) were not consistent with a KPC enzyme or metallo-lactamase. PCR and sequencing confirmed that E. coli 110833-1 harbored blaOXA-48, blaTEM-1, and blaOXA-1 (7, 17, 18) and belonged to the ST131 clonal group (4). E. coli 110833-1 harbored 2 plasmids of 61 kb and 4 kb (1). All 7 K. pneumoniae isolates were indistinguishable by pulsedfield gel electrophoresis (PFGE), and a 61-kb plasmid was detected in all cases (15). Multilocus sequence typing (MLST) was performed according to the method of Diancourt et al. (6) and indicated that all K. pneumoniae isolates belonged to ST913. Meropenem and ertapenem MICs for E. coli 110833-1 were 0.25 g/ml and 1.0 g/ml, respectively, as determined by Etest (AB Biodisk, Solna, Sweden), and the isolate was susceptible to ceftazidime, cefotaxime, cefpodoxime, aztreonam, cefoxitin, amikacin, kana-